Gd-EOB-DTPA Enhanced-MRI of the Liver: Dynamic Enhancement Compared with Gd-DTPA, Preliminary Experience

Natasha Wehrli¹, Hersh Chandarana¹, Ely Felker¹, Bachir Taouli, ^1,2

Gd-EOB-DTPA is a recently FDA approved liver-specific contrast agent which combines a dynamic and a delayed phase of enhancement, approved to be used at a lower dose compared to extracellular agents (0.025 vs. 0.1 mmol/kg). In this study, we compared hepatic vascular conspicuity obtained with single and double dose Gd-EOB vs. Gd-DTPA at the dynamic phase, and found significantly better liver-to-vessel contrast ratio with Gd-DTPA compared to single dose Gd-EOB-DTPA. The liver-to-vessel contrast ratio improved when using a double dose Gd-EOB-DTPA.